RU2377007C1 - Agent for treatment and prevention of oncologic diseases and method of application said agent (versions) - Google Patents
Agent for treatment and prevention of oncologic diseases and method of application said agent (versions) Download PDFInfo
- Publication number
- RU2377007C1 RU2377007C1 RU2008125190/15A RU2008125190A RU2377007C1 RU 2377007 C1 RU2377007 C1 RU 2377007C1 RU 2008125190/15 A RU2008125190/15 A RU 2008125190/15A RU 2008125190 A RU2008125190 A RU 2008125190A RU 2377007 C1 RU2377007 C1 RU 2377007C1
- Authority
- RU
- Russia
- Prior art keywords
- calcium
- treatment
- prevention
- cancer
- agent
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 19
- 229910052791 calcium Inorganic materials 0.000 claims description 19
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 16
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 12
- OYPRJOBELJOOCE-OUBTZVSYSA-N Calcium-41 Chemical compound [41Ca] OYPRJOBELJOOCE-OUBTZVSYSA-N 0.000 claims description 12
- 239000001110 calcium chloride Substances 0.000 claims description 12
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 8
- 235000005282 vitamin D3 Nutrition 0.000 claims description 8
- 239000011647 vitamin D3 Substances 0.000 claims description 8
- 229940021056 vitamin d3 Drugs 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 244000248349 Citrus limon Species 0.000 claims description 5
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000011787 zinc oxide Substances 0.000 claims description 4
- 229940056069 zinc oxide 15 mg Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000771 oncological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-IGMARMGPSA-N Calcium-40 Chemical compound [40Ca] OYPRJOBELJOOCE-IGMARMGPSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000004374 Insulin-like growth factor binding protein 3 Human genes 0.000 description 1
- 108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 1
- 241000785736 Pholis crassispina Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960005084 calcitriol Drugs 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000002758 colorectal adenoma Diseases 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005264 electron capture Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Изобретение относиться к области медицины и предназначено для лечения и профилактики онкологических заболеваний.The invention relates to medicine and is intended for the treatment and prevention of cancer.
В настоящее время для лечения онкологических заболеваний применяются следующие методы: хирургическое лечение, лучевое лечение, лекарственная терапия.Currently, the following methods are used for the treatment of cancer: surgical treatment, radiation treatment, drug therapy.
Применение данных методов зависит от ряда факторов: стадии опухолевого процесса, общего состояния пациента и т.д. Каждый из вышеперечисленных методов имеет четкие показания для применения, а также противопоказания и ряд побочных неблагоприятных воздействий, иногда приводивших к незапланированным перерывам в лечении или его отмене.The use of these methods depends on a number of factors: the stage of the tumor process, the general condition of the patient, etc. Each of the above methods has clear indications for use, as well as contraindications and a number of adverse side effects, sometimes leading to unplanned interruptions in treatment or its cancellation.
Были попытки применения средств, содержащих ядовитые (токсичные) компоненты, но в настоящее время ввиду низкой эффективности данные средства не применяются (RU №2035181, А61К 31/285, 1995 на «Средство для лечения лейкозов и способ лечения лейкозов»).There have been attempts to use drugs containing toxic (toxic) components, but at present, due to their low effectiveness, these drugs are not used (RU No. 2035181, А61К 31/285, 1995 on “Leukemia treatment and leukemia treatment method”).
Данное решение принято в качестве прототипа для заявленного объекта.This decision was made as a prototype for the claimed object.
Настоящее изобретение направлено на решение технической задачи по формированию нового механизма поглощения свободными радикалами высокочастотных квантов элементов раковых клеток на молекулярном уровне.The present invention is directed to solving the technical problem of forming a new mechanism for the absorption by free radicals of high-frequency quanta of cancer cell elements at the molecular level.
Достигаемый при этом технический результат заключается в повышении эффективности лечения и профилактики онкологических заболеваний в программах комплексного лечения.The technical result achieved in this case is to increase the effectiveness of treatment and prevention of cancer in complex treatment programs.
Указанный технический результат в части самого средства достигается тем, что средство для лечения и профилактики онкологических заболеваний, выполненное в жидкостной форме, включает в себя следующие компоненты в весовом количестве:The specified technical result in terms of the tool itself is achieved in that the tool for the treatment and prevention of cancer, made in liquid form, includes the following components in weight quantity:
лимонный сок - 1000-1100 млlemon juice - 1000-1100 ml
фруктоза - 1000-1100 гfructose - 1000-1100 g
этиловый спирт 40% - 500-550 млethyl alcohol 40% - 500-550 ml
хлористый кальций - 35-55 гcalcium chloride - 35-55 g
хлористый кальций (кальций-41) - 0,05-5 мгcalcium chloride (calcium-41) - 0.05-5 mg
оксид цинка - 1-12 гzinc oxide - 1-12 g
колекальциферол (витамин D3) - 0,15 мг (6000 ME)colecalciferol (Vitamin D 3 ) - 0.15 mg (6000 ME)
Указанный технический результат достигается тем, что средство для лечения и профилактики онкологических заболеваний, выполненное в таблетированной форме, включает в себя следующие компоненты в весовом количестве на 1 таблетку:The specified technical result is achieved in that the agent for the treatment and prevention of cancer, made in tablet form, includes the following components in a weight quantity of 1 tablet:
кальций (в виде карбоната кальция-40) - 600-700 мгcalcium (in the form of calcium carbonate-40) - 600-700 mg
колекальциферол (витамин D3) - 0,005-0,01 мг (200-400 ME)colecalciferol (vitamin D 3 ) - 0.005-0.01 mg (200-400 ME)
оксид цинка - 15 мгzinc oxide - 15 mg
хлористый кальций (кальций-41) - 0,001-0,01 мгcalcium chloride (calcium-41) - 0.001-0.01 mg
витамин Е - 5 мгVitamin E - 5 mg
Указанный технический результат в части способа применения этого средства достигается тем, что этот способ применения средства заключается в ежедневном приеме по 8-12 мл в виде раствора или по 1 таблетке в течение 3 месяцев с лечебной целью в программах комплексной терапии и 1 месяц в качестве профилактики.The specified technical result in terms of the method of using this agent is achieved by the fact that this method of using the agent consists in daily intake of 8-12 ml in the form of a solution or 1 tablet for 3 months for therapeutic purposes in complex therapy programs and 1 month as a prophylaxis .
Указанные признаки являются существенными и взаимосвязаны с образованием устойчивой совокупности существенных признаков, достаточной для получения требуемого технического результата.These features are significant and are interconnected with the formation of a stable set of essential features sufficient to obtain the desired technical result.
Согласно настоящего изобретения рассматривается средство для лечения и профилактики онкологических заболеваний.According to the present invention, an agent for the treatment and prevention of cancer is contemplated.
Науке на современном этапе известно о взаимодействии квантов с ядрами и атомами молекул клеток и их систем. Взаимодействие квантов с нуклонами ядер осуществляется с явлением поглощения их с увеличением массы ядра и переходом его в изомерное состояние с новыми свойствами. Так, например, при воздействии на воду (основной компонент по массе организма человека) квантами ультрафиолетового диапазона частот происходит образование перекиси водорода, которая обладает большим содержанием квантов в структуре молекулы относительно исходной системы молекул (Некрасов Б.В. «Основы общей химии», т.1, М, «Химия», 1965). Кроме этого, при взаимодействии атомов молекул клеток с квантами происходит явление изомерии, образование веществ, имеющих одинаковый элементарный состав, но разный молекулярный вес, вследствие этого отличающихся по некоторым свойствам (Перельман В.И. «Краткий справочник химика», М, «Химия», 1964).At the present stage, science is aware of the interaction of quanta with the nuclei and atoms of cell molecules and their systems. The interaction of quanta with nucleons of nuclei occurs with the phenomenon of their absorption with increasing mass of the nucleus and its transition to an isomeric state with new properties. So, for example, when water (the main component by mass of the human body) is exposed to quanta in the ultraviolet frequency range, hydrogen peroxide is formed, which has a high content of quanta in the structure of the molecule relative to the original molecular system (B. Nekrasov, “Fundamentals of General Chemistry,” t .1, M, Chemistry, 1965). In addition, the interaction of the atoms of cell molecules with quanta leads to the phenomenon of isomerism, the formation of substances having the same elementary composition, but different molecular weights, which therefore differ in some properties (Perelman VI, “Quick reference chemist”, M, “Chemistry” , 1964).
Взаимодействие высокочастотных квантов с атомами молекул клеток и их систем приводит к явлениям изомерии, образованию свободных радикалов, что сопровождается поломками в наследственном аппарате клеток. Также свободные радикалы могут возникать не только под влиянием квантов излучения - ионизирующего, ультрафиолетового и даже видимого спектров. Значительное количество свободных радикалов возникает в клетках (гепатоцитах) при метаболизации ксенобиотиков. Их генерация возможна при использовании многих лекарственных препаратов (антрациклины и др.). Присутствие на внешней орбите неспаренного электрона (например - ОН) позволяет им быть химически активными. В структуре ДНК имеются пуриновые кольца - молекулы аденина и гуанина, которые легко разрываются при взаимодействии со свободными радикалами. В других случаях происходит просто присоединение без разрыва ДНК и клетка с такой «дефектной» ДНК с большей степенью вероятности может преобразоваться в раковую. Следовательно, в основе онкологических заболеваний лежат высокочастотные кванты и их поглощение может обладать существенным профилактическим и лечебным эффектом.The interaction of high-frequency quanta with the atoms of the molecules of cells and their systems leads to phenomena of isomerism, the formation of free radicals, which is accompanied by breakdowns in the hereditary apparatus of cells. Also, free radicals can arise not only under the influence of radiation quanta - ionizing, ultraviolet, and even visible spectra. A significant amount of free radicals occurs in cells (hepatocytes) during the metabolism of xenobiotics. Their generation is possible using many drugs (anthracyclines, etc.). The presence of an unpaired electron (for example, OH) in the outer orbit allows them to be chemically active. The structure of DNA contains purine rings - adenine and guanine molecules, which are easily broken when interacting with free radicals. In other cases, DNA simply joins without breaking, and a cell with such “defective” DNA is more likely to be converted to cancer. Therefore, oncological diseases are based on high-frequency quanta and their absorption can have a significant prophylactic and therapeutic effect.
Такими поглотителями квантов («квантодепрессантами») могут быть различные химические элементы с возбужденными ядрами, обладающие свойствами захватывать орбитальные электроны, с поглощением высокочастотных квантов.Such absorbers of quanta (“quantum depressants”) can be various chemical elements with excited nuclei, which have the ability to capture orbital electrons, with the absorption of high-frequency quanta.
Общая формула электронного захватаGeneral formula for electronic capture
р++е-→n+νe p + + e - → n + ν e
Атом при электронном захвате переходит в возбужденное состояние с внутренней оболочкой без электрона (или, как говорят, с «дыркой», вакансией на внутренней оболочке). Снятие возбуждения атомной оболочки происходит путем перехода на нижний уровень электрона с одной из верхних оболочек, причем образовавшуюся на более высокой оболочке вакансию может заполнить электрон с еще более высокой оболочки и т.д.An atom during electron capture transforms into an excited state with an inner shell without an electron (or, as they say, with a “hole”, a vacancy on the inner shell). The excitation of the atomic shell is removed by going to the lower electron level from one of the upper shells, and the vacancy formed on the higher shell can be filled by an electron from an even higher shell, etc.
Такими свойствами обладают радионуклиды кальция, йода, бериллия, цинка и др.These properties are possessed by radionuclides of calcium, iodine, beryllium, zinc, etc.
В ряде исследований установлена взаимосвязь между потреблением высоких доз кальция и снижением риска развития рака толстой кишки и рака молочной железы (U.Peters, N.Chatterjee, К.A.McGlynn, R.Е.Schoen, Т.R.Church et. al. Calcium intake and colorectal adenoma in a US colorectal cancer early detection program. - American Journal of Clinical Nutrition, Vol.80, No.5, 1358-1365, November 2004; Jennifer Lin, PhD; JoAnn E. Manson, MD, DrPH; I-Min Lee, MBBS, ScD; Nancy R. Cook, ScD; Julie E. Buring, ScD; Shumin M. Zhang, MD, ScD. Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women.-Arch Intern Med. 2007; 167: 1050-1059; Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. - Am J Clin Nutr. 2007 Jun; 85(6): 1586-91). В настоящее время изотоп кальция-41 широкого применяется в ряде научных и клинических центров в качестве маркера поражения костей скелета при раке молочной железы и раке простаты (Freeman, S.P.H.T. and Beck, В. and Bierman, J.M. and Caffee, M.W. and Heaney, R.P. and Holloway, L. and Marcus, R. and Southon, J.R. and Vogel, J.S. The study of skeletal calcium metabolism with Ca-41 and Ca-45. - Nuclear Instruments and Methods in Physics Research Section B - Beam Interactions with Materials and Atoms 172: pp.930-933; Detecting Bone Cancer. - Lawrence Livermore National Laboratory., Cancer S&TR December 2006). Определено избирательное накопление изотопа в метастатических очагах, а также в первичной опухоли. Механизм действия препарата заключается в действии кальция, кальция-41, связанного с поглощением высокочастотных квантов, выраженным антиоксидантным эффектом. С учетом всего вышеизложенного данный препарат может быть использован для профилактики онкологических заболеваний и в программах комплексного лечения.A number of studies have found a relationship between high calcium intake and a lower risk of colon cancer and breast cancer (U. Peters, N. Chatterjee, K. A. McGlynn, R. E. Schoen, T. R. Church et. Al Calcium intake and colorectal adenoma in a US colorectal cancer early detection program. - American Journal of Clinical Nutrition, Vol. 80, No.5, 1358-1365, November 2004; Jennifer Lin, PhD; JoAnn E. Manson, MD, DrPH ; I-Min Lee, MBBS, ScD; Nancy R. Cook, ScD; Julie E. Buring, ScD; Shumin M. Zhang, MD, ScD. Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women.-Arch Intern Med . 2007; 167: 1050-1059; Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. - Am J Clin Nutr. 2007 Jun; 85 (6): 1586-91). Currently, the calcium-41 isotope is widely used in a number of scientific and clinical centers as a marker for skeletal bone damage in breast and prostate cancer (Freeman, SPHT and Beck, B. and Bierman, JM and Caffee, MW and Heaney, RP and Holloway, L. and Marcus, R. and Southon, JR and Vogel, JS The study of skeletal calcium metabolism with Ca-41 and Ca-45 .-- Nuclear Instruments and Methods in Physics Research Section B - Beam Interactions with Materials and Atoms 172 : pp. 930-933; Detecting Bone Cancer. - Lawrence Livermore National Laboratory., Cancer S&TR December 2006). The selective accumulation of the isotope in metastatic foci, as well as in the primary tumor, was determined. The mechanism of action of the drug is the action of calcium, calcium-41, associated with the absorption of high-frequency quanta, a pronounced antioxidant effect. Given the above, this drug can be used for the prevention of cancer and in complex treatment programs.
Для профилактики и лечения онкологических заболеваний предлагается квантопоглощающее средство, состоящее из активного начала (изотопов кальция-40 и кальция-41) и вспомогательных компонентов. Представляются две формы: первая в виде раствора и вторая - в виде таблеток.For the prevention and treatment of cancer, a quantum-absorbing agent is proposed, consisting of the active principle (calcium-40 and calcium-41 isotopes) and auxiliary components. Two forms are presented: the first in the form of a solution and the second in the form of tablets.
Весовое количество компонентов для жидкостной формы (раствор)The weight number of components for the liquid form (solution)
1. лимонный сок - 1000-1100 мл1. lemon juice - 1000-1100 ml
2. фруктоза - 1000-1100 г2. fructose - 1000-1100 g
3. этиловый спирт 40% - 500-550 мл3. ethyl alcohol 40% - 500-550 ml
4. хлористый кальций - 35-55 г4. calcium chloride - 35-55 g
5. хлористый кальций (кальций-41) - 0,05-5 мг5. calcium chloride (calcium-41) - 0.05-5 mg
6. оксид цинка - 1-12 г6. zinc oxide - 1-12 g
7. колекальциферол (витамин D3) - 0,15 мг (6000 ME)7. colecalciferol (Vitamin D 3 ) - 0.15 mg (6000 ME)
Таблетированная форма (состав и дозировка действующих веществ на 1 таблетку):Tablet form (composition and dosage of active substances per 1 tablet):
1. кальций (в виде карбоната кальция-40) - 600-700 мг1. calcium (in the form of calcium carbonate-40) - 600-700 mg
2. колекальциферол (витамин D3) - 0,005-0,01 мг (200-400 ME)2. colecalciferol (vitamin D 3 ) - 0.005-0.01 mg (200-400 ME)
3. оксид цинка - 15 мг3. zinc oxide - 15 mg
4. хлористый кальций (кальций-41) - 0,001-0,01 мг4. calcium chloride (calcium-41) - 0.001-0.01 mg
5. витамин Е - 5 мг5. Vitamin E - 5 mg
Наличие в предлагаемом нами комплексе аскорбиновой кислоты ("лимонный сок), витамина Е, кальция, цинка и др. будет оказывать антиоксидантный эффект и способствовать снижению образования свободных радикалов. Описано несколько возможных механизмов действия кальция, приводящих к снижению риска развития онкологических заболеваний. Первый за счет изменения концентрации 1. 25-дигидроксивитамина D3 (1,25-dihydroxyvitamin D 3), который может ингибировать клеточную пролиферацию и индуцировать дифференпировку клеток (Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 2001; 23: 87-92; Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442-7). Вторым возможным механизмом принято считать повышение концентрации в плазме инсулинозависимого фактора роста I (insulin-like growth factor-l) в ответ на увеличение концентрации кальция (Stem JS, et al. Dietary changes favorably affect bone remodeling in older adults. J AmDietAssoc 1999:99: 1228-33; Gunnel! D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M, et al. Are dietprostate cancer associations mediated by the IGF axis? A crosssectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003; 88: 1682-6).The presence in our complex of ascorbic acid ("lemon juice), vitamin E, calcium, zinc, etc. will have an antioxidant effect and help to reduce the formation of free radicals. Several possible mechanisms of calcium action are described that lead to a lower risk of cancer. First for by changing the concentration of 1. 25-dihydroxyvitamin D 3 (1,25-dihydroxyvitamin D 3), which can inhibit cell proliferation and induce cell differentiation (Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 2001; 23: 87-92; Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998; 58: 442-7.) The second possible mechanism is considered to be an increase in the plasma concentration of insulin-like growth factor I in response to an increase in calcium concentration (Stem JS, et al. Dietary changes favorably affect bone remodeling in older adults. J AmDietAssoc 1999: 99: 1228-33; Gunnel! D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M, et al. Are dietprostate cancer associations mediated by the IGF axis? A crosssectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003; 88: 1682-6).
Способ применения средства заключается в ежедневном приеме по 8-12 мл в виде раствора или по 1 таблетке в сутки. В качестве профилактики онкологических заболеваний предлагается использовать препарат в течение 1 месяца в «группах риска», у лиц, имеющих контакт с ионизирующим излучением, СВЧ, высокоактивными химическими реагентами и т.д. Программы лечения будут иметь индивидуализированный подход с учетом распространенности опухолевого процесса, гистологической структуры опухоли, общего состояния пациента. Сроки лечения составят от 3 до 6 месяцев. Применение препарата может осуществляться в комплексе со стандартными методами лечения онкологических больных (хирургия-химиотерапия, лучевая терапия).The method of application of the drug consists in daily intake of 8-12 ml in the form of a solution or 1 tablet per day. As a prophylaxis of oncological diseases, it is proposed to use the drug for 1 month in “risk groups”, in persons who have contact with ionizing radiation, microwave, highly active chemicals, etc. Treatment programs will have an individualized approach, taking into account the prevalence of the tumor process, the histological structure of the tumor, and the general condition of the patient. The terms of treatment will be from 3 to 6 months. The use of the drug can be carried out in combination with standard methods of treatment of cancer patients (surgery, chemotherapy, radiation therapy).
Пример 1Example 1
Пациент Т, 77 лет. У пациента в 2002 году диагностирован рак простаты T3N0M0. Проведена лучевая терапия до СОД=70 Гр в последующем периоде в течение трех месяцев принимал препарат, на фоне проводимого лечения достигнута положительная динамика в виде уменьшения размеров опухоли, снижения уровня ПСА. Находится под наблюдением, данных за прогрессирование заболевания не получено.Patient T, 77 years old. A patient was diagnosed with prostate cancer T3N0M0 in 2002. Radiation therapy was carried out to SOD = 70 Gy in the subsequent period for three months he took the drug, against the background of the treatment, positive dynamics were achieved in the form of a decrease in the size of the tumor, a decrease in the PSA level. It is under observation, data for the progression of the disease has not been received.
Пример 2Example 2
Пациентка С, 62 лет. 5 лет назад диагностирован рак правой молочной железы Т2 N2MQ. Выполнена правосторонняя мастэктомия. От дальнейшего лечения (химиотерапия) больная отказалась, проведен курс терапии препаратом в течение 3 месяцев. Находится под наблюдением, данных за прогрессирование заболевания не подучено.Patient C, 62 years old. 5 years ago, right breast cancer T2 N2MQ was diagnosed. Performed a right-sided mastectomy. The patient refused further treatment (chemotherapy), a course of drug therapy was carried out for 3 months. It is under observation, data for the progression of the disease has not been learned.
Claims (4)
лимонный сок 1000-1100 мл
фруктоза 1000-1100 г
этиловый спирт 40% 500-550 мл
хлористый кальций 35-55 г
хлористый кальций (кальций-41) 0,05-5 мг
оксид цинка 1-12 г
колекальциферол (витамин D3) 0,15 мг (6000 ME)1. The tool for the treatment and prevention of cancer, which is a liquid form, characterized in that it includes the following components in weight quantity:
lemon juice 1000-1100 ml
fructose 1000-1100 g
ethyl alcohol 40% 500-550 ml
calcium chloride 35-55 g
calcium chloride (calcium-41) 0.05-5 mg
zinc oxide 1-12 g
colecalciferol (Vitamin D 3 ) 0.15 mg (6000 ME)
кальций (в виде карбоната кальция-40) 600-700 мг
колекальциферол (витамин D3) 0,005-0,01 мг (200-400 ME)
оксид цинка 15 мг
хлористый кальций (кальций-41) 0,001-0,01 мг
витамин Е 5 мг.2. The tool for the treatment and prevention of cancer, which is a tablet form, characterized in that it includes the following components in a weight quantity of 1 tablet:
calcium (in the form of calcium carbonate-40) 600-700 mg
colecalciferol (Vitamin D 3 ) 0.005-0.01 mg (200-400 ME)
zinc oxide 15 mg
calcium chloride (calcium-41) 0.001-0.01 mg
Vitamin E 5 mg.
лимонный сок 1000-1100 мл
фруктоза 1000-1100 г
этиловый спирт 40% 500-550 мл
хлористый кальций 35-55 г
хлористый кальций (кальций-41) 0,05-5 мг
оксид цинка 1-12 г
колекальциферол (витамин D3) 0,15 мг (6000 ME)3. The method of using the agent for the treatment and prevention of cancer, which consists in daily intake for 3 months for therapeutic purposes in complex therapy programs and 1 month as a prophylaxis of 8-12 ml in the form of a solution that includes the following components in weight quantity :
lemon juice 1000-1100 ml
fructose 1000-1100 g
ethyl alcohol 40% 500-550 ml
calcium chloride 35-55 g
calcium chloride (calcium-41) 0.05-5 mg
zinc oxide 1-12 g
colecalciferol (Vitamin D 3 ) 0.15 mg (6000 ME)
кальций (в виде карбоната кальция-40) 600-700 мг
колекальциферол (витамин D3) 0,005-0,01 мг (200-400 ME)
оксид цинка 15 мг
хлористый кальций (кальций-41) 0,001-0,01 мг
витамин Е 5 мг. 4. The method of using the agent for the treatment and prevention of cancer, which consists in daily intake for 3 months for therapeutic purposes in complex therapy programs and 1 month as a prophylaxis for 1 tablet, which includes the following components in a weight quantity of 1 tablet:
calcium (in the form of calcium carbonate-40) 600-700 mg
colecalciferol (Vitamin D 3 ) 0.005-0.01 mg (200-400 ME)
zinc oxide 15 mg
calcium chloride (calcium-41) 0.001-0.01 mg
Vitamin E 5 mg.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008125190/15A RU2377007C1 (en) | 2008-06-23 | 2008-06-23 | Agent for treatment and prevention of oncologic diseases and method of application said agent (versions) |
| PCT/RU2008/000619 WO2009157799A1 (en) | 2008-06-23 | 2008-09-18 | Agent for treating and preventing oncological diseases and a method for the use of said agent (variants) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008125190/15A RU2377007C1 (en) | 2008-06-23 | 2008-06-23 | Agent for treatment and prevention of oncologic diseases and method of application said agent (versions) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2377007C1 true RU2377007C1 (en) | 2009-12-27 |
Family
ID=41444725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008125190/15A RU2377007C1 (en) | 2008-06-23 | 2008-06-23 | Agent for treatment and prevention of oncologic diseases and method of application said agent (versions) |
Country Status (2)
| Country | Link |
|---|---|
| RU (1) | RU2377007C1 (en) |
| WO (1) | WO2009157799A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA77660C2 (en) * | 2000-10-03 | 2007-01-15 | Compositions and methods for reducing plasma lipoprotein a level in human | |
| US7273607B2 (en) * | 2002-07-01 | 2007-09-25 | Karl G. Schakel, legal representative | Health enhancement method |
| KR100528720B1 (en) * | 2002-08-29 | 2005-11-15 | 주식회사 메디넥스 | Nutritional composition of health food inhibiting heavy metal accumulation |
| RU2262240C1 (en) * | 2004-01-28 | 2005-10-20 | Закрытое акционерное общество "Компания "Нутритек" (ЗАО "Компания "Нутритек") | Food for enteral feeding |
-
2008
- 2008-06-23 RU RU2008125190/15A patent/RU2377007C1/en not_active IP Right Cessation
- 2008-09-18 WO PCT/RU2008/000619 patent/WO2009157799A1/en active Application Filing
Non-Patent Citations (1)
| Title |
|---|
| http://www.lor-homeopat.m/php/content.php?id=1120. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009157799A1 (en) | 2009-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rondanelli et al. | Pivotal role of boron supplementation on bone health: A narrative review | |
| WO2014138101A1 (en) | Gene signature to predict homologous recombination (hr) deficient cancer | |
| ArulJothi et al. | Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions | |
| RU2373185C2 (en) | Mechano-activated amorphous and amorphous-crystalline calcium salts of gluconic acid, compositions, methods of production, pharmaceutical preparations and method of treatment based on said preparations | |
| Mou et al. | Study on the hypnotic effect of rare protopanaxadiol-type and protopanaxatriol-type ginsenosides | |
| RU2377007C1 (en) | Agent for treatment and prevention of oncologic diseases and method of application said agent (versions) | |
| Lajer et al. | Erosive potential of saliva stimulating tablets with and without fluoride in irradiated head and neck cancer patients | |
| Krakoff | Use of allopurinol in preventing hyperuricemia in leukemia and lymphoma | |
| Roblin et al. | Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn’s disease | |
| RU2391109C1 (en) | Medication for treatment of oncologic diseases with application of calcium - 41 isotope | |
| Ungjaroenwathana et al. | Lime powder regimen supplement alleviates urinary metabolic abnormalities in urolithiasis patients | |
| Di Gianvincenzo et al. | Supramolecular citrate poly allylamine hydrochloride nanoparticles for citrate delivery and calcium oxalate nanocrystal dissolution | |
| US20080260857A1 (en) | Substance and Method for Treating Neoplasms | |
| Khandelwal et al. | Free radical biology of diabetes mellitus | |
| Kim et al. | Enhancement of 1, 25-dihydroxyvitamin D3-and all-trans retinoic acid-induced HL-60 leukemia cell differentiation by Panax ginseng | |
| Roman et al. | High-definition FT-IR reveals a synergistic effect on lipid accumulation in prostate cancer cells induced by a combination of X-rays and radiosensitizing drugs | |
| JP2023504233A (en) | Formulations for reducing or preventing oxidative stress damage | |
| Usluoğullari et al. | What is the effect of radioiodine therapy on Helicobacter pylori infection? | |
| Gamag et al. | Prevalence of Vitamin B12 Deficiency in Libyan Type 2 Diabetic Patients Treated with Metformin | |
| Svart et al. | 3-Hydroxybutyrate administration elevates plasma parathyroid hormone in a pilot human randomized, controlled, cross over trial | |
| Ogidi et al. | In vitro antioxidant and anti-inflammatory activities of selected polyherbal formulations sold in Nigeria | |
| Khrutmuang et al. | Effect of multivitamin on serum 25-hydroxy vitamin D level in postmenopausal women: A randomized, double-blind, placebo-controlled trial | |
| Razmara et al. | The Effect of Vitamins and Minerals on Dental Implants: A Review | |
| Mandal et al. | Plasma leptin concentrations and lipid profile in Bosnian healthy and Type 2 diabetic individuals | |
| Yasmin et al. | FOLIC ACID;: IS SIMPLE FOLIC ACID EFFECTIVE TO REPLENISH RBC FOLATE STORES AMONG PAKISTANI FEMAL EPATIENTS? SMALL CASE. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120624 |